CURRICULUM VITAE

David W. Schwartz

MD, FAAFP, CAQ Geriatrics

E-mail:Schwartz@VikingCR.com

Primary Investigator/Sub-Investigator

Viking Clinical Research, Ltd.

29645 Rancho California Road, Suite 133

Temecula, California 92591

Office:(800) 670-4960

Fax: (800) 670-4969

Associated Sites:

David Schwartz, M.D., Private Practice
29645 Rancho California Road, Suite 133
Temecula, CA 92591

Beverly Health Care (now Country Villa)
Member of Admitting Staff
Murrieta, CA

Inland Valley Regional Medical Center
Active in Family Practice
Wildomar, CA

Viking Clinical Research
24910 Las Brisas Road, Suite 122
Murrieta, CA 92562

Licenses and Certificates:

California Medical License	G20562
DEA/Narcotics License	AS8435958
Physician Assistant Supervisor License	SA21334
Board Certified Emergency Medicine	1987-1998
Board Certified Family Practice	1978-Current
Board Certified Qualification in Geriatrics	1998-Current

Research Experience:

GlaxoSmithKline: A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Efficacy and Safety of Flexible Dose Extended-Release Bupropion Hydrochloride (HCl) xxx-xxx mg/day and Placebo Administered for Eight Weeks for the Treatment of Adult Outpatients with Major Depressive Disorder Including Symptoms of Decreased Energy, Pleasure, and Interest. 2003-2004.

GlaxoSmithKline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple xxx Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain of Non-Malignant Origin. 2003-2004.

GlaxoSmithKline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride xxx mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer. 2003-2008.

Kos Pharmaceuticals: The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients with Intermittent Claudication – a Matrix Design. 2003-2004.

Bristol-Myers Squibb: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Safety and Efficacy of BMS XXX as Monotherapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control. 2003-2004.

Novartis: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (xxx mg) and Hydrochlorothiazide (xxx and xxx mg) Combined and Alone, Valsartan xxx mg and Valsartan xxx mg / Hydrochlorothiazide xxx mg in Hypertensive Patients. 2003-2004.

Novartis: Post-text Supplement #1: Pharmacogenetic Sub-Study for the Study Listed Above. 2003-2004.

Novartis: Post-text Supplement #2: A 54-Week Open-Label Extension to a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (xxx mg) and Hydrochlorothiazide (xxx and xxx mg) Combined and Alone, Valsartan xxx mg and Valsartan xxx mg / Hydrochlorothiazide xxx mg in Hypertensive Patients. 2004.

Eli Lilly and Company: Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS). 2004-2005.

Novartis: A 16 week, randomized, double-blind, active-controlled, parallel group study to evaluate the effect on insulin sensitivity of valsartan (xxxmg) and hydrochorothiazide (xxmg) combined and alone, in patients with metabolic syndrome. 2004-2005.

Novartis: Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP): A Multicenter, Randomized, Open-label, 2-Arm Parallel Group Study to Evaluate the Efficacy of Moderate Vs. Aggressive Antihypertensive Therapy with Diovan® and Diovan HCT® to Reduce Blood Pressure and Plasma hsCRP levels in Patients with Stage 2 Hypertension. 2004-2005.

Aventis: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes of Telithromycin versus Azithromycin in Outpatients with Community-Acquired Lower Respiratory Tract Infections. 2004-2005.

Sankyo: A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of Co-Administration of xxx plus xxx Compared to Monotherapy in Patients with Mild to Severe Hypertension. 2005.

Watson: A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Comparison of the Efficacy and Safety of Fixed-Dose Extended-Release xxxx/xxxx in the Relief of Moderate to Moderately Severe Chronic Osteoarthritis Pain of the Hip or Knee. 2004.

Pfizer Inc: A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations of Immediate Release and Modified Release Formulations of xxx in Adult Male Subjects with Erectile Dysfunction. 2004-2005.

GlaxoSmithKline: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (xxxmg-xxxmg once daily) in Elderly Subjects with Major Depressive Disorder. 2004-2005.

Pfizer Inc: A Randomized, Double Blind, Placebo Controlled, Four Arm Study to Evaluate the Clinical Efficacy of xxx in Men who have frequency and urgency, with or without urinary urge incontinence, with or without bladder outlet obstruction. 2005-2006.

Pfizer Inc: A Phase 2, 8-week, Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Tolerability and Safety of xxx for Stress Urinary Incontinence in Women. 2006.

Pfizer Inc: A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects with Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of xxx plus a Mood Stabilizer (vs Placebo plus a Mood Stabilizer) Following a Minimum of 4 Months of Response to Open-Label Treatment with Both Agents. 2006-2008.

Sanofi Aventis: An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study with XXX as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of XX in Outpatients with MDD. 2006-2007.

Novartis: A 6-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Combination of Valsartan/HCTZ (xx/xxmg) With Forced Titration to a Maximum Dose of xx/xxmg) Compared to Valsartan Monotherapy (xxmg With Forced Titration to xxmg) as Initial Therapy in Patients with Severe Hypertension. 2006-2007.

Novartis: An 8-Week, Multicenter, Randomized, Double-blind, Parallel-Group Study to Evaluate the Efficacy and Safety of the Combination of XX/XX/XX Compared to XX/XX, XX/XX, and XX/XX in Patients with Moderate to Severe Hypertension. 2006-2007.

Merck: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential-Design Study to Evaluate the Lipid-Altering Efficacy and Tolerabillity of XX-XXXX in Patients with Dyslipidemia. 2006-2007.

Merck: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of XXX in Postmenopausal Women with Overactive Bladder. 2006-2007.

King: A Randomized, Double-Blind, Multicenter, Parallel-Study Evaluating the Efficacy and Safety of a Combination of XX Plus XXX Versus the Component Monotherapies in Subjects with Essential Hypertension (Stage 1 or 2). 2006-2007.

Takeda: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of XXX and XX in Subjects with Type 2 Diabetes. 2006-2008.

Novartis: A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With XXX in Overactive Bladder Patients Dissatisfied With Previous Anticholinergic Therapy. 2006-2007.

GlaxoSmithKline: A 12 Week Flexible Dose Study of XXX, Placebo and Active Control in the Treatment of Social Anxiety Disorder (SocAD). 2006-2007.

Novartis: An 8-Week, Randomized, Fixed-Dose, Placebo-Controlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and Tolerability of XXX and XX mg in the Treatment of Major Depressive Disorder (MDD). 2006-2008.

Sanofi-Aventis: A Multi-Center, Double-Blind, Parallel Group, Fixed Dose, 4-Arm, Placebo and XXX Controlled 8-Week Efficacy Study of 2 Oral Doses of XXX in Adult Outpatients with Major Depressive Disorder. 2007-2008.

Pfizer: A Phase III, Randomized, Double-Blind-Parallel Group, 10 Week Placebo Controlled Fixed Dose Study of XXXX and Paroxetine Evaluating the Efficacy and Safety of XXXX for the Treatment of Generalized Anxiety Disorder. 2008-2009

Novartis: Randomized, Double Blind, Controlled, Parallel Group, 12-Week Treatment Study to Compare the Efficacy and Safety of the Combination of XXX Once Daily With Open Label Tiotropium Once Daily Versus Open Label Tiotropium Once Daily in Patient's With Moderate to Severe Chronic Obstructive Pulmonary Disease. 2009-2010

Novartis: A 24-Week, Prospective, Randomized, Parallel Group, double-Blind Multi-Center Study Comparing the Effects of XXX Patch 15cm2 Vs. XXX Patch 5cm2 on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type 2009-2011

Novartis: An 8-Week Randomized Double Blind, Parallel Group Multicenter Active Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of XXX HCTS Compared to XXXX in Patients with Stage 2 Systolic Hypertension and Diabetes Mellitus 2009-2010

Novartis: An 8-Week Randomized Double Blind Parallel Multi-Center Forced Titration Study to Evaluate the Safety and Efficacy of XXX plus HCTZ Versus XXX Monotherapy in Metabolic Syndrome Patients with Stage 2 Hypertension 2009-2010

Forest: Metabolic Effects of XXX Compared to XXXXER in Hypertensive Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose 2009-2010

Cephalon: A Double Blind, Placebo Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of ********** in Adults with Major Depression Associated with Bipolar I Disorder 2010-2011

Novartis: An 8-Week, Randomized, Double Blind. Placebo Controlled, Parallel Group, Multi-Center Study of the Efficacy and Safety of ********* 0.5mg and 1mg Sublingual Tablets Administered Once Daily in Patients with Major Depressive Disorder (MDD) 2010-2011

Novartis: A 12-week, Randomized, Multi-center, Open-Label, *********, (12-24mg/day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole 2010-2012

Pfizer: A Phase IV, Multicenter, Randomized, 8-week, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy Of 2 Fixed Doses (50 AND 100 MG/DAY) Of ********** In Adult Outpatients with Major Depressive Disorder. 2011-2012

Otsuka: A **P**hase 3, Multicenter, Rand**o**mized, Double-blind, **P**lacebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of ******** as **A**djunctive Ther**a**py **i**n the Treatment of Adults with Major Depre**s**sive Disorder 2011-2014

Otsuka: A Long-term, Phase 3, Multicenter, **O**pen-label **T**rial to Evaluate the Safety and Tolera**b**ility of **O**ral ******* as Adju**n**ctive Therapy in Adults with Major Depressive Disorder, 2011-2014

Eli Lilly: A Randomized Placebo-Controlled, Double-Blind Study of ******** Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment 2012-2013

Forest: A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of ********* and ********* Given as a Fixed-Dose Combination in Patients With Stage 1 or 2 Essential Hypertension 2012-2013

Forest: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ******* AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER 2012-

Forest: A PHASE 3, LONG-TERM, OPEN-LABEL STUDY OF SAFETY AND TOLERABILITY OF ******* AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER. 2012-

Forest: A Double-Blind, Placebo-Controlled, Flexible-Dose Study of ******** in Patients with Generalized Anxiety Disorder. 2012-2014

Otsuka: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXXXXXXXXXX as Maintenance Treatment in Patients with Bipolar I Disorder 2013-

Avanir: A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of XXXXXXXXXX for the treatment of symptoms of agitation in patients with Alzheimer's disease. 2013-2014

Avanir: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of XXXXXXXXXX for the treatment of agitation in patients with dementia of the Alzheimer's type 2015-

Professional Experience:

Investigator, Viking Clinical Research Temecula, CA	2003-Present
Private Practice, Primary Care Medicine with Special Interest in Geriatrics Temecula, CA	1990-Present
Emergency Medicine California	1982-1990
Family Practice Arizona	1978-1982

Family Practice — 1972-1978
California

Education:

Bachelor of Science Degree — 1966
Major: Engineering
Cal Tech, Pasadena, CA

MD Degree — 1970
UCLA, Los Angeles, CA

Fellowship in Anesthesiology — 1968
Cedar-Sinai Medical Center, Los Angeles, CA

Internship and Residency — 1972
Cedar-Sinai Medical Center, Los Angeles, CA

Presentation Experience:

Speaker Training and PowerPoint Presentation lectures geared toward healthcare professionals for the following companies:

Merck	(GSK) Beecham/Avandia	AstraZeneca	Sankyo
Eli Lilly/Zyprexa	Schering/Clarinex	Biovail Pharmaceuticals	Novartis/Exelon
Wyeth-Ayerst/Effexor	Pfizer/Bextra	Aventis	Janssen
Abbott/Mobic	KOS/Advicor	Forest Labs	

Hospital Staff Appointments:

Rancho Springs Medical Center — 2000-2002
Chairman Credential Committee
Murrieta, CA

Beverly Healthcare — 1999-2000
Medical Director
Murrieta, CA

Rancho Springs Medical Center — 1996-2000
Chairman Family Practice Committee
Murrieta, CA

Nation's Hospice — 1998-1999
Medical Director